160 related articles for article (PubMed ID: 32229353)
1. Clinical features of newly developed NF2 intracranial meningiomas through comparative analysis of pediatric and adult patients.
Li P; Wu T; Wang Y; Zhao F; Wang Z; Wang X; Wang B; Yang Z; Liu P
Clin Neurol Neurosurg; 2020 Jul; 194():105799. PubMed ID: 32229353
[TBL] [Abstract][Full Text] [Related]
2. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.
Goutagny S; Bah AB; Henin D; Parfait B; Grayeli AB; Sterkers O; Kalamarides M
Neuro Oncol; 2012 Aug; 14(8):1090-6. PubMed ID: 22711605
[TBL] [Abstract][Full Text] [Related]
4. Clinical course and management of intracranial meningiomas in neurofibromatosis type 2 patients.
Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(6):367-72. PubMed ID: 26652870
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis type 2-associated meningiomas: an international multicenter study of outcomes after Gamma Knife stereotactic radiosurgery.
Mohammed N; Hung YC; Xu Z; Chytka T; Liscak R; Tripathi M; Arsanious D; Cifarelli CP; Perez Caceres M; Mathieu D; Speckter H; Mehta GU; Lekovic GP; Sheehan JP
J Neurosurg; 2022 Jan; 136(1):109-114. PubMed ID: 34144518
[TBL] [Abstract][Full Text] [Related]
6. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients.
Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M
J Neurosurg; 2020 May; 134(5):1377-1385. PubMed ID: 32442973
[TBL] [Abstract][Full Text] [Related]
7. 3D Volumetric Measurement of Neurofibromatosis Type 2-Associated Meningiomas: Association Between Tumor Location and Growth Rate.
Evers S; Verbaan D; Sanchez E; Peerdeman S
World Neurosurg; 2015 Oct; 84(4):1062-9. PubMed ID: 26087434
[TBL] [Abstract][Full Text] [Related]
8. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
[TBL] [Abstract][Full Text] [Related]
9. Childhood and adolescent meningiomas: a report of 38 cases and review of literature.
Menon G; Nair S; Sudhir J; Rao BR; Mathew A; Bahuleyan B
Acta Neurochir (Wien); 2009 Mar; 151(3):239-44; discussion 244. PubMed ID: 19238320
[TBL] [Abstract][Full Text] [Related]
10. Growth Dynamics of Intracranial Tumors in Patients with Neurofibromatosis Type 2.
Lawson McLean AC; Rosahl SK
World Neurosurg; 2017 Feb; 98():152-161. PubMed ID: 27777160
[TBL] [Abstract][Full Text] [Related]
11. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
[TBL] [Abstract][Full Text] [Related]
12. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
14. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases.
Perry A; Giannini C; Raghavan R; Scheithauer BW; Banerjee R; Margraf L; Bowers DC; Lytle RA; Newsham IF; Gutmann DH
J Neuropathol Exp Neurol; 2001 Oct; 60(10):994-1003. PubMed ID: 11589430
[TBL] [Abstract][Full Text] [Related]
15. Intracranial meningiomas and neurofibromatosis type 2.
Aboukais R; Zairi F; Baroncini M; Bonne NX; Schapira S; Vincent C; Lejeune JP
Acta Neurochir (Wien); 2013 Jun; 155(6):997-1001; discussion 1001. PubMed ID: 23558725
[TBL] [Abstract][Full Text] [Related]
16. Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2007 Dec; 28(8):1083-90. PubMed ID: 18043434
[TBL] [Abstract][Full Text] [Related]
17. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas.
Antinheimo J; Haapasalo H; Haltia M; Tatagiba M; Thomas S; Brandis A; Sainio M; Carpen O; Samii M; Jääskeläinen J
J Neurosurg; 1997 Oct; 87(4):610-4. PubMed ID: 9322850
[TBL] [Abstract][Full Text] [Related]
18. Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas.
Pemov A; Dewan R; Hansen NF; Chandrasekharappa SC; Ray-Chaudhury A; Jones K; Luo W; Heiss JD; Mullikin JC; Chittiboina P; Stewart DR; Asthagiri AR
Sci Rep; 2020 Jul; 10(1):12563. PubMed ID: 32724039
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
Nunes FP; Merker VL; Jennings D; Caruso PA; di Tomaso E; Muzikansky A; Barker FG; Stemmer-Rachamimov A; Plotkin SR
PLoS One; 2013; 8(3):e59941. PubMed ID: 23555840
[TBL] [Abstract][Full Text] [Related]
20. A role for the p53 pathway in the pathology of meningiomas with NF2 loss.
Chang Z; Guo CL; Ahronowitz I; Stemmer-Rachamimov AO; MacCollin M; Nunes FP
J Neurooncol; 2009 Feb; 91(3):265-70. PubMed ID: 18974932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
